ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Medication company Viatris (NASDAQ:VTRS) in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s ...

Viatris Inc. (VTRS) recently reported a fourth quarter that fell short of Wall Street expectations, missing revenue and earnings targets. The ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...

Jazz Pharmaceuticals JAZZ reported fourth-quarter 2024 adjusted earnings of $6.60 per share, which beat the Zacks Consensus ...

Capricor Therapeutics, Inc.'s Deramiocel receives FDA Priority Review for DMD cardiomyopathy, with a decision by Aug. 2025.

The anti-diversity initiatives are visible in the chamber. Trump removed Chairman of the Joint Chiefs of Staff Charles Q.

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Belgium 10 Year Government Bond 0.0000 2.9212% ...